InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,290.86
(
2.02%
)
US TECH 100
17,844.40
(
2.47%
)
Dow Jones
39,253.27
(
1.42%
)
Brent Oil
76.87
(
-0.38%
)
Bitcoin
56,824.54
(
5.24%
)
Post# of 3329
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

califax

Send PM Follow Ignore
Followers 24
Posts 3015
Boards Moderated 0
Alias Born 01/18/2009

califax

Re: None

Monday, 01/25/2010 8:36:23 AM

Monday, January 25, 2010 8:36:23 AM

Post# of 3329
Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm
Conference Call to Discuss Data to be Held on Thursday, January 28th at 9am EST

Monday January 25, 2010, 8:30 am
http://finance.yahoo.com/news/Keryx-Reports-Statistically-prnews-2783803.html?x=0&.v=1

posts are IMHO // either news - with LINK

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up